

**CONTROLLED SUBSTANCE SCHEDULE -
AMENDMENTS**

2008 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Paul Ray

Senate Sponsor: _____

LONG TITLE

General Description:

This bill modifies the Controlled Substances Act by adding salvia divinorum as a controlled substance.

Highlighted Provisions:

This bill:

- ▶ adds the herb salvia divinorum to the statutory list of controlled substances; and
- ▶ designates salvia divinorum as a Schedule I controlled substance.

Monies Appropriated in this Bill:

None

Other Special Clauses:

None

Utah Code Sections Affected:

AMENDS:

58-37-4, as last amended by Laws of Utah 2006, Chapter 8

Be it enacted by the Legislature of the state of Utah:

Section 1. Section **58-37-4** is amended to read:

58-37-4. Schedules of controlled substances -- Schedules I through V -- Findings required -- Specific substances included in schedules.



(1) There are established five schedules of controlled substances known as Schedules I, II, III, IV, and V which shall consist of substances listed in this section.

(2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the official name, common or usual name, chemical name, or brand name designated:

(a) Schedule I:

(i) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation:

(A) Acetyl-alpha-methylfentanyl
(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);

(B) Acetylmethadol;

(C) Allylprodine;

(D) Alphacetylmethadol, except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;

(E) Alphameprodine;

(F) Alphamethadol;

(G) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);

(H) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

(I) Benzethidine;

(J) Betacetylmethadol;

(K) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);

(L) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;

(M) Betameprodine;

(N) Betamethadol;

(O) Betaprodine;

(P) Clonitazene;

- 59 (Q) Dextromoramide;
60 (R) Diampromide;
61 (S) Diethylthiambutene;
62 (T) Difenoxin;
63 (U) Dimenoxadol;
64 (V) Dimepheptanol;
65 (W) Dimethylthiambutene;
66 (X) Dioxaphetyl butyrate;
67 (Y) Dipipanone;
68 (Z) Ethylmethylthiambutene;
69 (AA) Etonitazene;
70 (BB) Etoxeridine;
71 (CC) Furethidine;
72 (DD) Hydroxypethidine;
73 (EE) Ketobemidone;
74 (FF) Levomoramide;
75 (GG) Levophenacylmorphane;
76 (HH) Morpheridine;
77 (II) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
78 (JJ) Noracymethadol;
79 (KK) Norlevorphanol;
80 (LL) Normethadone;
81 (MM) Norpipanone;
82 (NN) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]
83 propanamide;
84 (OO) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
85 (PP) Phenadoxone;
86 (QQ) Phenampromide;
87 (RR) Phenomorphan;
88 (SS) Phenoperidine;
89 (TT) Piritramide;

90 (UU) Proheptazine;
91 (VV) Properidine;
92 (WW) Propiram;
93 (XX) Racemoramide;
94 (YY) Salvia divinorum;
95 [~~YY~~] (ZZ) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-
96 propanamide;
97 [~~ZZ~~] (AAA) Tilidine;
98 [~~AAA~~] (BBB) Trimeperidine;
99 [~~BBB~~] (CCC) 3-methylfentanyl, including the optical and geometric isomers
100 (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); and
101 [~~CCC~~] (DDD) 3-methylthiofentanyl
102 (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide).
103 (ii) Unless specifically excepted or unless listed in another schedule, any of the
104 following opium derivatives, their salts, isomers, and salts of isomers when the existence of the
105 salts, isomers, and salts of isomers is possible within the specific chemical designation:
106 (A) Acetorphine;
107 (B) Acetyldihydrocodeine;
108 (C) Benzylmorphine;
109 (D) Codeine methylbromide;
110 (E) Codeine-N-Oxide;
111 (F) Cyprenorphine;
112 (G) Desomorphine;
113 (H) Dihydromorphine;
114 (I) Drotebanol;
115 (J) Etorphine (except hydrochloride salt);
116 (K) Heroin;
117 (L) Hydromorphenol;
118 (M) Methyldesorphine;
119 (N) Methylhydromorphine;
120 (O) Morphine methylbromide;

- 121 (P) Morphine methylsulfonate;
122 (Q) Morphine-N-Oxide;
123 (R) Myrophine;
124 (S) Nicocodeine;
125 (T) Nicomorphine;
126 (U) Normorphine;
127 (V) Pholcodine; and
128 (W) Thebacon.
- 129 (iii) Unless specifically excepted or unless listed in another schedule, any material,
130 compound, mixture, or preparation which contains any quantity of the following hallucinogenic
131 substances, or which contains any of their salts, isomers, and salts of isomers when the
132 existence of the salts, isomers, and salts of isomers is possible within the specific chemical
133 designation; as used in this Subsection (2)(iii) only, "isomer" includes the optical, position, and
134 geometric isomers:
- 135 (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;
136 α -ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; α -ET; and AET;
137 (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
138 4-bromo-2,5-dimethoxy- α -methylphenethylamine; 4-bromo-2,5-DMA;
139 (C) 4-bromo-2,5-dimethoxypenethylamine, some trade or other names:
140 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;
141 (D) 2,5-dimethoxyamphetamine, some trade or other names:
142 2,5-dimethoxy- α -methylphenethylamine; 2,5-DMA;
143 (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
144 (F) 4-methoxyamphetamine, some trade or other names:
145 4-methoxy- α -methylphenethylamine; paramethoxyamphetamine, PMA;
146 (G) 5-methoxy-3,4-methylenedioxyamphetamine;
147 (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:
148 4-methyl-2,5-dimethoxy- α -methylphenethylamine; "DOM"; and "STP";
149 (I) 3,4-methylenedioxy amphetamine;
150 (J) 3,4-methylenedioxymethamphetamine (MDMA);
151 (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-

152 alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
153 (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
154 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
155 (M) 3,4,5-trimethoxy amphetamine;
156 (N) Bufotenine, some trade and other names:
157 3-(β -Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,
158 N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
159 (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
160 (P) Dimethyltryptamine, some trade or other names: DMT;
161 (Q) Ibogaine, some trade and other names:
162 7-Ethyl-6,6 β ,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino
163 [5,4-b] indole; Tabernanthe iboga;
164 (R) Lysergic acid diethylamide;
165 (S) Marijuana;
166 (T) Mescaline;
167 (U) Parahexyl, some trade or other names:
168 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;
169 (V) Peyote, meaning all parts of the plant presently classified botanically as
170 *Lophophora williamsii* Lemaire, whether growing or not, the seeds thereof, any extract from
171 any part of such plant, and every compound, manufacture, salts, derivative, mixture, or
172 preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));
173 (W) N-ethyl-3-piperidyl benzilate;
174 (X) N-methyl-3-piperidyl benzilate;
175 (Y) Psilocybin;
176 (Z) Psilocyn;
177 (AA) Tetrahydrocannabinols, synthetic equivalents of the substances contained in the
178 plant, or in the resinous extractives of *Cannabis*, sp. and/or synthetic substances, derivatives,
179 and their isomers with similar chemical structure and pharmacological activity such as the
180 following: Δ 1 cis or trans tetrahydrocannabinol, and their optical isomers Δ 6 cis or trans
181 tetrahydrocannabinol, and their optical isomers Δ 3,4 cis or trans tetrahydrocannabinol, and its
182 optical isomers, and since nomenclature of these substances is not internationally standardized,

183 compounds of these structures, regardless of numerical designation of atomic positions
184 covered;

185 (BB) Ethylamine analog of phencyclidine, some trade or other names:
186 N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
187 N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;

188 (CC) Pyrrolidine analog of phencyclidine, some trade or other names:
189 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;

190 (DD) Thiophene analog of phencyclidine, some trade or other names:
191 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and
192 (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.

193 (iv) Unless specifically excepted or unless listed in another schedule, any material
194 compound, mixture, or preparation which contains any quantity of the following substances
195 having a depressant effect on the central nervous system, including its salts, isomers, and salts
196 of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
197 specific chemical designation:

198 (A) Mecloqualone; and
199 (B) Methaqualone.

200 (v) Any material, compound, mixture, or preparation containing any quantity of the
201 following substances having a stimulant effect on the central nervous system, including their
202 salts, isomers, and salts of isomers:

203 (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or
204 4,5-dihydro-5-phenyl-2-oxazolamine;

205 (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,
206 alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;

207 (C) Fenethylamine;

208 (D) Methcathinone, some other names: 2-(methyldamino)-propionophenone;
209 alpha-(methyldamino)propionophenone; 2-(methyldamino)-1-phenylpropan-1-one;
210 alpha-N-methyldaminopropionophenone; monomethylpropion; ephedrone; N-methylcathinone;
211 methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of
212 optical isomers;

213 (E) (±)cis-4-methyldaminorex ((±)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);

- 214 (F) N-ethylamphetamine; and
215 (G) N,N-dimethylamphetamine, also known as
216 N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
- 217 (vi) Any material, compound, mixture, or preparation which contains any quantity of
218 the following substances, including their optical isomers, salts, and salts of isomers, subject to
219 temporary emergency scheduling:
- 220 (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
221 (B) N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
- 222 (vii) Unless specifically excepted or unless listed in another schedule, any material,
223 compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate
224 (gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.
- 225 (b) Schedule II:
- 226 (i) Unless specifically excepted or unless listed in another schedule, any of the
227 following substances whether produced directly or indirectly by extraction from substances of
228 vegetable origin, or independently by means of chemical synthesis, or by a combination of
229 extraction and chemical synthesis:
- 230 (A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or
231 opiate, excluding apomorphine, dextrophan, nalbuphine, nalmefene, naloxone, and naltrexone,
232 and their respective salts, but including:
- 233 (I) Raw opium;
234 (II) Opium extracts;
235 (III) Opium fluid;
236 (IV) Powdered opium;
237 (V) Granulated opium;
238 (VI) Tincture of opium;
239 (VII) Codeine;
240 (VIII) Ethylmorphine;
241 (IX) Etorphine hydrochloride;
242 (X) Hydrocodone;
243 (XI) Hydromorphone;
244 (XII) Metopon;

- 245 (XIII) Morphine;
246 (XIV) Oxycodone;
247 (XV) Oxymorphone; and
248 (XVI) Thebaine;
- 249 (B) Any salt, compound, derivative, or preparation which is chemically equivalent or
250 identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these
251 substances may not include the isoquinoline alkaloids of opium;
- 252 (C) Opium poppy and poppy straw;
- 253 (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
254 any salt, compound, derivative, or preparation which is chemically equivalent or identical with
255 any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives,
256 and salts of isomers and derivatives, whether derived from the coca plant or synthetically
257 produced, except the substances may not include decocainized coca leaves or extraction of coca
258 leaves, which extractions do not contain cocaine or ecgonine; and
- 259 (E) Concentrate of poppy straw, which means the crude extract of poppy straw in either
260 liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy.
- 261 (ii) Unless specifically excepted or unless listed in another schedule, any of the
262 following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
263 ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific
264 chemical designation, except dextrorphan and levopropoxyphene:
- 265 (A) Alfentanil;
266 (B) Alphaprodine;
267 (C) Anileridine;
268 (D) Bezitramide;
269 (E) Bulk dextropropoxyphene (nondosage forms);
270 (F) Carfentanil;
271 (G) Dihydrocodeine;
272 (H) Diphenoxylate;
273 (I) Fentanyl;
274 (J) Isomethadone;
275 (K) Levo-alpha-acetylmethadol, some other names: levo-alpha-acetylmethadol,

- 276 levomethadyl acetate, or LAAM;
- 277 (L) Levomethorphan;
- 278 (M) Levorphanol;
- 279 (N) Metazocine;
- 280 (O) Methadone;
- 281 (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
- 282 (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic
- 283 acid;
- 284 (R) Pethidine (meperidine);
- 285 (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 286 (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 287 (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 288 (V) Phenazocine;
- 289 (W) Piminodine;
- 290 (X) Racemethorphan;
- 291 (Y) Racemorphan;
- 292 (Z) Remifentanyl; and
- 293 (AA) Sufentanyl.
- 294 (iii) Unless specifically excepted or unless listed in another schedule, any material,
- 295 compound, mixture, or preparation which contains any quantity of the following substances
- 296 having a stimulant effect on the central nervous system:
- 297 (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 298 (B) Methamphetamine, its salts, isomers, and salts of its isomers;
- 299 (C) Phenmetrazine and its salts; and
- 300 (D) Methylphenidate.
- 301 (iv) Unless specifically excepted or unless listed in another schedule, any material,
- 302 compound, mixture, or preparation which contains any quantity of the following substances
- 303 having a depressant effect on the central nervous system, including its salts, isomers, and salts
- 304 of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
- 305 specific chemical designation:
- 306 (A) Amobarbital;

- 307 (B) Glutethimide;
308 (C) Pentobarbital;
309 (D) Phencyclidine;
310 (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
311 1-piperidinocyclohexanecarbonitrile (PCC); and
312 (F) Secobarbital.
- 313 (v) Unless specifically excepted or unless listed in another schedule, any material,
314 compound, mixture, or preparation which contains any quantity of Phenylacetone.
315 Some of these substances may be known by trade or other names: phenyl-2-propanone,
316 P2P; benzyl methyl ketone, methyl benzyl ketone.
- 317 (vi) Nabilone, another name for nabilone:
318 (±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
319 6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
- 320 (c) Schedule III:
321 (i) Unless specifically excepted or unless listed in another schedule, any material,
322 compound, mixture, or preparation which contains any quantity of the following substances
323 having a stimulant effect on the central nervous system, including its salts, isomers whether
324 optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers,
325 and salts of isomers is possible within the specific chemical designation:
- 326 (A) Those compounds, mixtures, or preparations in dosage unit form containing any
327 stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were
328 listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the
329 Code of Federal Regulations, and any other drug of the quantitative composition shown in that
330 list for those drugs or which is the same except that it contains a lesser quantity of controlled
331 substances;
- 332 (B) Benzphetamine;
333 (C) Chlorphentermine;
334 (D) Clortermine; and
335 (E) Phendimetrazine.
- 336 (ii) Unless specifically excepted or unless listed in another schedule, any material,
337 compound, mixture, or preparation which contains any quantity of the following substances

338 having a depressant effect on the central nervous system:

339 (A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
340 pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients
341 which are not listed in any schedule;

342 (B) Any suppository dosage form containing amobarbital, secobarbital, or
343 pentobarbital, or any salt of any of these drugs which is approved by the Food and Drug
344 Administration for marketing only as a suppository;

345 (C) Any substance which contains any quantity of a derivative of barbituric acid or any
346 salt of any of them;

347 (D) Chlorhexadol;

348 (E) Buprenorphine;

349 (F) Any drug product containing gamma hydroxybutyric acid, including its salts,
350 isomers, and salts of isomers, for which an application is approved under the federal Food,
351 Drug, and Cosmetic Act, Section 505;

352 (G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine:
353 $\pm$ -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;

354 (H) Lysergic acid;

355 (I) Lysergic acid amide;

356 (J) Methyprylon;

357 (K) Sulfondiethylmethane;

358 (L) Sulfonethylmethane;

359 (M) Sulfonmethane; and

360 (N) Tiletamine and zolazepam or any of their salts, some trade or other names for a
361 tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine:
362 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam:
363 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,
364 flupyrazapon.

365 (iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
366 U.S. Food and Drug Administration approved drug product, some other names for dronabinol:
367 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or
368 (-)-delta-9-(trans)-tetrahydrocannabinol.

(iv) Nalorphine.

(v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:

(A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

(B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts;

(C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;

(D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;

(E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts;

(F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;

(G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts; and

(H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, non-narcotic ingredients in recognized therapeutic amounts.

(vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids including any of the following or any isomer, ester, salt, or derivative of the following that promotes muscle growth:

(A) Boldenone;

- 400 (B) Chlorotestosterone (4-chlortestosterone);
401 (C) Clostebol;
402 (D) Dehydrochlormethyltestosterone;
403 (E) Dihydrotestosterone (4-dihydrotestosterone);
404 (F) Drostanolone;
405 (G) Ethylestrenol;
406 (H) Fluoxymesterone;
407 (I) Formebolone (formebolone);
408 (J) Mesterolone;
409 (K) Methandienone;
410 (L) Methandranone;
411 (M) Methandriol;
412 (N) Methandrostenolone;
413 (O) Methenolone;
414 (P) Methyltestosterone;
415 (Q) Mibolerone;
416 (R) Nandrolone;
417 (S) Norethandrolone;
418 (T) Oxandrolone;
419 (U) Oxymesterone;
420 (V) Oxymetholone;
421 (W) Stanolone;
422 (X) Stanozolol;
423 (Y) Testolactone;
424 (Z) Testosterone; and
425 (AA) Trenbolone.
- 426 Anabolic steroids expressly intended for administration through implants to cattle or
427 other nonhuman species, and approved by the Secretary of Health and Human Services for use,
428 may not be classified as a controlled substance.
- 429 (d) Schedule IV:
430 (i) Unless specifically excepted or unless listed in another schedule, any material,

431 compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not
432 less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them.

433 (ii) Unless specifically excepted or unless listed in another schedule, any material,
434 compound, mixture, or preparation which contains any quantity of the following substances,
435 including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and
436 salts of isomers is possible within the specific chemical designation:

- 437 (A) Alprazolam;
- 438 (B) Barbitol;
- 439 (C) Bromazepam;
- 440 (D) Butorphanol;
- 441 (E) Camazepam;
- 442 (F) Chloral betaine;
- 443 (G) Chloral hydrate;
- 444 (H) Chlordiazepoxide;
- 445 (I) Clobazam;
- 446 (J) Clonazepam;
- 447 (K) Clorazepate;
- 448 (L) Clotiazepam;
- 449 (M) Cloxazolam;
- 450 (N) Delorazepam;
- 451 (O) Diazepam;
- 452 (P) Dichloralphenazone;
- 453 (Q) Estazolam;
- 454 (R) Ethchlorvynol;
- 455 (S) Ethinamate;
- 456 (T) Ethyl loflazepate;
- 457 (U) Fludiazepam;
- 458 (V) Flunitrazepam;
- 459 (W) Flurazepam;
- 460 (X) Halazepam;
- 461 (Y) Haloxazolam;

462 (Z) Ketazolam;
463 (AA) Loprazolam;
464 (BB) Lorazepam;
465 (CC) Lormetazepam;
466 (DD) Mebutamate;
467 (EE) Medazepam;
468 (FF) Meprobamate;
469 (GG) Methohexital;
470 (HH) Methylphenobarbital (mephobarbital);
471 (II) Midazolam;
472 (JJ) Nimetazepam;
473 (KK) Nitrazepam;
474 (LL) Nordiazepam;
475 (MM) Oxazepam;
476 (NN) Oxazolam;
477 (OO) Paraldehyde;
478 (PP) Pentazocine;
479 (QQ) Petrichloral;
480 (RR) Phenobarbital;
481 (SS) Pinazepam;
482 (TT) Prazepam;
483 (UU) Quazepam;
484 (VV) Temazepam;
485 (WW) Tetrazepam;
486 (XX) Triazolam;
487 (YY) Zaleplon; and
488 (ZZ) Zolpidem.
489 (iii) Any material, compound, mixture, or preparation of fenfluramine which contains
490 any quantity of the following substances, including its salts, isomers whether optical, position,
491 or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of
492 isomers is possible.

(iv) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers whether optical, position, or geometric isomers, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:

(A) Cathine ((+)-norpseudoephedrine);

(B) Diethylpropion;

(C) Fencamfamine;

(D) Fenproporex;

(E) Mazindol;

(F) Mefenorex;

(G) Modafinil;

(H) Pemoline, including organometallic complexes and chelates thereof;

(I) Phentermine;

(J) Pipradrol;

(K) Sibutramine; and

(L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).

(v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.

(e) Schedule V: Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

(i) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;

(ii) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;

(iii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;

(iv) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of

524 atropine sulfate per dosage unit;
525 (v) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
526 (vi) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of
527 atropine sulfate per dosage unit; and
528 (vii) unless specifically exempted or excluded or unless listed in another schedule, any
529 material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant
530 effect on the central nervous system, including its salts, isomers, and salts of isomers.

Legislative Review Note
as of 6-11-07 2:56 PM

Office of Legislative Research and General Counsel

H.B. 260 - Controlled Substance Schedule - Amendments

Fiscal Note

2008 General Session

State of Utah

State Impact

Enactment of this bill will not require additional appropriations.

Individual, Business and/or Local Impact

Enactment of this bill likely will not result in direct, measurable costs and/or benefits for individuals, businesses, or local governments.
